BioSpace News Archive

Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a leader in science-based approaches to enhancing the quality and nutritional value of crops and food ingredients, today announced the closing of a transaction resulting in gross cash proceeds to the company of approximately $6.8 million,

In lieu of a daily in-person update to the media, Dr. Theresa Tam, Canada’s Chief Public Health Officer, issued the following statement

Retractable Technologies, Inc. (NYSE American: RVP) reports that its operating income was $481 thousand in the first quarter of 2020, compared to an operating loss for the same period last year of $175 thousand, and that overall unit sales for the first quarter of 2020 increased 39.2% over same period in the prior year.

PANTHERx® Rare Pharmacy announces that it has been selected by Deciphera Pharmaceuticals as a limited distribution partner for new drug QINLOCK™ (ripretinib)

Enzychem Lifesciences, today announced that Dr. Cameron Robert Wolfe, associate professor of medicine at Duke University School of Medicine, an internationally renowned specialist in infectious diseases, has been appointed to lead the Company’s U.S COVID-19 efforts of the development of EC-18 as a COVID-19 therapeutic drug.

Renalytix AI plc (LSE: RENX), a commercial-stage artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announces that it has confidentially submitted a draft registration statement on Form F-1 with the Securities and Exchange Commission

Data science firm Civis Analytics released new findings from its COVID-19 Impact Research, funded by the Bill & Melinda Gates Foundation.

Citius Pharmaceuticals Inc. (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced the closing of the previously announced registered direct offering priced at-the-market under Nasdaq rules

20/20 GeneSystems, Inc. announced today that it will offer in its CLIA laboratory a COVID-19 antibody test that received an Emergency Use Authorization (EUA) from the FDA on May 3.

Comprehensive MDHealthPro program includes COVID-19 testing, safety supplies, and monitoring services.